Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
 BACK TO LIST

Laboratory Report

Patient
Name: Dörschner, , Gülsen,
DOB: 30-JUL-1970 (Age: 55)
Gender: female
Address:
Patbergplatz 571
56068 Koblenz (Germany)
ID: 3549-346619-3 (ECI)
Report
Date: 11-FEB-2024
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
Brüderhaus Koblenz
Kardinal-Krementz-Straße 1-5
56068 Koblenz (Germany)
Specimen
Collected: 11-FEB-2024

Chemistry

Test 11-FEB-2024 Reference Range Unit
Cholesterol [Mass/volume] in Serum or Plasma 183.0 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 133.5 35 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 92.8 0 - 130 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 63.5 40 - 100 mg/dL

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
All lipid parameters are within normal limits. No evidence of dyslipidemia. These results suggest a favorable cardiovascular risk profile from a laboratory perspective. Continued monitoring as per clinical guidelines is recommended.